Tang-feng Lv
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study.
Journal: Translational lung cancer research
Published: November 19, 2020
Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non-Small Cell Lung Cancer and Response to EGFR TKIs.
Journal: Translational oncology
Published: December 12, 2019
Geranylgeranyl diphosphate synthase 1 knockout ameliorates ventilator-induced lung injury via regulation of TLR2/4-AP-1 signaling.
Journal: Free radical biology & medicine
Published: September 24, 2019
LncRNA GMDS-AS1 inhibits lung adenocarcinoma development by regulating miR-96-5p/CYLD signaling.
Journal: Cancer medicine
Published: September 14, 2019
Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.
Journal: Cancer science
Published: September 10, 2019
18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of benign pulmonary lesions in sarcoidosis.
Journal: Translational lung cancer research
Published: August 02, 2019
Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.
Journal: Cancer medicine
Published: June 18, 2019
Zebrafish Xenograft Model of Human Lung Cancer for Evaluating Osimertinib Resistance.
Journal: BioMed research international
Published: April 17, 2019
Inhibition of GGPPS1 attenuated LPS-induced acute lung injury and was associated with NLRP3 inflammasome suppression.
Journal: American journal of physiology. Lung cellular and molecular physiology
Published: January 18, 2019
A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib.
Journal: Clinical lung cancer
Published: December 20, 2018
A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib.
Journal: Cancer biology & therapy
Published: August 11, 2018
TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib.
Journal: Journal of thoracic disease
Published: July 13, 2018
Last Updated: 09/26/2026